CME Group Balance Sheet Health
Financial Health criteria checks 6/6
CME Group has a total shareholder equity of $26.6B and total debt of $3.4B, which brings its debt-to-equity ratio to 12.9%. Its total assets and total liabilities are $202.0B and $175.4B respectively. CME Group's EBIT is $4.5B making its interest coverage ratio -0.7. It has cash and short-term investments of $2.5B.
Key information
12.86%
Debt to equity ratio
US$3.42b
Debt
| Interest coverage ratio | -0.7x |
| Cash | US$2.52b |
| Equity | US$26.62b |
| Total liabilities | US$175.38b |
| Total assets | US$201.99b |
Recent financial health updates
No updates
Recent updates
Analysis Article • Jun 18
CME Group (CME) Stock Could Be 18% Undervalued After CEO Succession News
CME Group (CME) stock is in focus after the company confirmed a leadership transition that will see long time Chairman and CEO Terry Duffy move to Executive Chairman while President and CFO Lynne Fitzpatrick becomes CEO in 2027. See our latest analysis for CME Group. The leadership announcement landed against a weaker backdrop for CME Group stock, with the share price down 3.46% over the past day and 17.23% over the past 30 days, while the 5 year total shareholder return of 45.07% still...Seeking Alpha • Jun 16
CME: An Extreme Session Per Decade Has Become One Per Month
Summary CME Group benefits from heightened volatility and record derivatives volumes, driven by regime shifts in Fed policy and persistent macro uncertainty. Recent years show a structural increase in extreme trading sessions, with open interest and leveraged basis trades reaching unprecedented levels. I assign a Buy rating to CME, as its toll-collecting model thrives amid disagreement over rates and ongoing funding guarantees from the Fed. Normalization poses the main risk, but even in that scenario, CME offers a 4.2% dividend yield and trades near 23x earnings. Read the full article on Seeking Alpha
Narrative Update • Jun 05
CME: Crypto And AI Futures Expansion Will Shape Future Earnings Power
Analysts have trimmed their average price target for CME Group to about $306.47. This reflects concerns that revenue momentum could soften as geopolitical volatility eases and that fresh competition in bitcoin perpetual futures may weigh on exchange valuations, even as several firms still see the competitive risk as manageable.Narrative Update • May 15
CME: Mixed Street Views And New Markets Will Shape Future Earnings Power
Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.Narrative Update • Apr 27
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.Narrative Update • Apr 11
CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.Narrative Update • Mar 26
CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.Narrative Update • Mar 11
CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.Narrative Update • Feb 25
CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.Narrative Update • Feb 10
CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.Narrative Update • Jan 27
CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.Narrative Update • Jan 12
CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.Narrative Update • Dec 27
CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.Narrative Update • Dec 13
CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.Narrative Update • Nov 16
CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.Seeking Alpha • Apr 27
CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
CME Group At A New All-Time High - Valuation Concerns Justified?
Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking AlphaFinancial Position Analysis
Short Term Liabilities: CME's short term assets ($169.0B) exceed its short term liabilities ($166.0B).
Long Term Liabilities: CME's short term assets ($169.0B) exceed its long term liabilities ($9.4B).
Debt to Equity History and Analysis
Debt Level: CME's net debt to equity ratio (3.4%) is considered satisfactory.
Reducing Debt: CME's debt to equity ratio has reduced from 13% to 12.9% over the past 5 years.
Debt Coverage: CME's debt is well covered by operating cash flow (129.1%).
Interest Coverage: CME earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 03:43 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CME Group Inc. is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |